Skip to main content
    P

    Procept Biorobotics Corp (PRCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $20.62
    +0.35 (+1.73%)

    Market Cap: $1.23B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(13/22)
    Avg Surprise
    -0.48%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.27
    Range$-0.41 - $-0.21
    12 analysts
    Revenue Consensus
    $121M
    Range$110M - $128M
    14 analysts
    Last 12 of 28 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.27$-0.41 - $-0.21--12--
    Sep 26
    Reported Nov 4
    		$-0.46$-0.39$-0.42 - $-0.34-17.95%Miss11
    0
    9
    30d
    		-21.1%
    Jun 26
    Reported Aug 4
    		$-0.47$-0.46$-0.51 - $-0.36-2.17%Miss10
    1
    1
    30d
    		-34.3%
    Mar 26
    Reported Apr 29
    		$-0.56$-0.56$-0.61 - $-0.48+0.00%Beat10
    0
    8
    30d
    		-24.4%
    Dec 25
    Reported Feb 25
    		$-0.53$-0.32$-0.35 - $-0.28-63.43%Miss9
    0
    3
    30d
    		-51.4%
    Sep 25
    Reported Nov 4
    		$-0.38$-0.42$-0.45 - $-0.38+9.52%Beat9
    1
    7
    30d
    		+5.0%
    Jun 25
    Reported Aug 6
    		$-0.35$-0.41$-0.49 - $-0.31+14.63%Beat10
    1
    0
    30d
    		+30.0%
    Mar 25
    Reported Apr 24
    		$-0.45$-0.49$-0.51 - $-0.47+8.16%Beat8
    0
    4
    30d
    		+11.8%
    Dec 24
    Reported Feb 25
    		$-0.35$-0.34$-0.44 - $-0.32-2.94%Miss8
    2
    0
    30d
    		+35.2%
    Sep 24
    Reported Oct 28
    		$-0.40$-0.49$-0.51 - $-0.44+18.37%Beat7
    1
    0
    30d
    		+21.6%
    Jun 24
    Reported Aug 1
    		$-0.50$-0.52$-0.55 - $-0.50+3.85%Beat8
    No revisions (30d)
    		+10.7%
    Mar 24
    Reported May 1
    		$-0.51$-0.56$-0.61 - $-0.49+8.93%Beat8
    No revisions (30d)
    		+19.0%
    Dec 23
    Reported Feb 27
    		$-0.54$-0.45$-0.50 - $-0.40-20.00%Miss8
    No revisions (30d)
    		+3.6%

    Key Metrics

    Valuation
    P/E Ratio-10.21EV/EBITDAN/A
    Price/FCF-13.89xFCF Yield-7.20%
    Profitability
    Profit Margin-32.50%Operating Margin-32.10%
    ROE-30.20%ROIC-29.23%
    Financial Health
    Debt/Equity0.16xInterest Coverage-32.62x
    Current Ratio5.89xQuick Ratio4.73x
    Trading Statistics
    Beta0.84Avg Volume1.32M
    52-Week High$38.1152-Week Low$16.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$20.15
    SMA 20$19.44
    SMA 50$19.32
    SMA 200$23.07
    EMA 10$20.13
    EMA 20$19.66
    EMA 50$19.57
    EMA 200$24.02

    MACD

    Line: 0.48Signal: 0.30Hist: 0.18

    ADX

    ADX: 26.5+DI: 31.4-DI: 12.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon DownN/A
    PSAR$24.07

    Bollinger Bands

    Upper Band$21.59
    Lower Band$17.29
    %B Position2211%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    56.5

    Momentum Oscillators

    Stoch %K52.3
    Stoch %D63.8
    Williams %R-58.0
    ROC (10d)3.3%
    Momentum0.66
    CCI (20d)69.3
    MFI (14d)52.9

    Volatility Measures

    ATR (14d)$1.37(6.6%)
    StdDev (20d)1.07
    Hist Vol73.3%(High)

    Volume Flow

    VWAP$20.27
    OBV-38.5M
    AD Line-12.1M
    CMF (20d)0.026

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.3x
    VWMA (20d)$19.60

    Pivot Points

    R3$26.98
    R2$25.52
    R1$22.90
    Pivot Point$21.44
    S1$18.82
    S2$17.36
    S3$14.74

    Advanced Oscillators

    TSI11.28
    Ultimate Osc44.6
    KST78.85

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$98.29M$94.50M$83.13M$76.38M$83.33M$79.18M$69.16M$68.24M$58.37M$53.35M$44.54M$43.58M
    Cost of Revenue$33.14M$32.12M$29.18M$30.07M$29.32M$27.44M$25.00M$24.56M$21.46M$21.87M$19.50M$22.33M
    Gross Profit$65.15M$62.38M$53.95M$46.31M$54.01M$51.75M$44.16M$43.67M$36.91M$31.48M$25.03M$21.25M
    Operating Expenses$92.52M$89.77M$86.55M$77.35M$77.20M$73.94M$71.60M$63.38M$59.34M$58.31M$52.68M$50.81M
    R&D$20.01M$20.10M$21.46M$19.06M$18.19M$17.63M$16.40M$15.07M$16.65M$17.50M$13.08M$14.50M
    SG&A$72.51M$69.67M$65.09M$58.30M$59.01M$56.30M$55.20M$48.32M$42.69M$40.81M$39.60M$36.32M
    Operating Income$-27,376,000$-27,390,000$-32,606,000$-31,040,000$-23,192,000$-22,189,000$-27,438,000$-19,710,000$-22,427,000$-26,828,000$-27,649,000$-29,559,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$856,000$842,000$818,000$895,000$919,000$895,000$877,000$969,000$1.14M$1.03M$1.04M$1.13M
    Income Before Tax$-26,574,000$-26,767,000$-31,681,000$-29,656,000$-21,377,000$-19,442,000$-24,784,000$-18,488,000$-20,974,000$-25,626,000$-25,957,000$-27,426,000
    Income Tax Expense$-58,000$94,000$-43,000$0$34,000$136,000$-47,000$0$0$0$0$0
    Net Income$-26,516,000$-26,861,000$-31,638,000$-29,846,000$-21,411,000$-19,578,000$-24,737,000$-18,856,000$-20,974,000$-25,626,000$-25,957,000$-27,506,000
    EBITDA$-23,178,000$-23,936,000$-29,128,000$-27,052,000$-18,840,000$-16,959,000$-22,432,000$-16,066,000$-18,506,000$-23,327,000$-23,728,000$-24,983,000
    EBIT$-25,718,000$-25,925,000$-30,863,000$-28,761,000$-20,458,000$-18,547,000$-23,907,000$-17,519,000$-19,834,000$-24,596,000$-24,912,000$-26,301,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRCT

    News

    Will Hydros Adoption Change PROCEPT BioRobotics Stock Narrative

    PROCEPT BioRobotics reported Q3 2026 revenue of US$98.3 million and a net loss of US$26.5 million, with its performance heavily driven by Hydros adoption. The company reiterated its full-year 2026 revenue guidance...

    Simply Wall St•11/6/26•Neutral

    PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Lags Revenue Estimates

    PROCEPT BioRobotics Corporation (PRCT) reported a Q3 loss of $0.46 per share, missing the Zacks Consensus Estimate of a $0.39 loss, and revenues of $98.29 million...

    Yahoo! Finance Canada•11/5/26•Bearish

    PROCEPT BioRobotics Q3 2026 Earnings Call Transcript

    PROCEPT BioRobotics reported Q3 2026 revenue of $98.3 million, an 18% year-over-year increase, driven by a 22% rise in U.S. procedures and a successful transition to Hydros systems. The company maintains its 2026 revenue...

    Benzinga•11/4/26•Bullish

    An 18% revenue rise comes with a wider Q3 loss at PROCEPT BioRobotics (PRCT).

    PROCEPT BioRobotics (PRCT) reported an 18% increase in third-quarter revenue to $98.3 million and a 19% rise in nine-month revenue to $275.9 million. Despite this revenue growth...

    Stock Titan•11/4/26•Somewhat-Bearish

    PROCEPT BioRobotics 2026: Revenue $98.29M, Net income ($26.52M), EPS ($0.46) — 10-Q Summary

    PROCEPT BioRobotics (PRCT) reported a 18% increase in revenue to $98.29 million for 2026, though its net loss widened to $26.52 million and diluted loss per share grew to $0.46. The company's nine-month revenue also rose...

    TradingView•11/4/26•Somewhat-Bearish

    PRCT Valuation and Fair Value

    P/E
    -10.2x
    P/FCF
    -13.9x
    P/B
    3.6x
    See GNG's fair value

    PRCT Profitability: Margins, ROIC and FCF

    Gross margin
    64.7%
    Operating margin
    -32.1%
    Net margin
    -32.5%
    ROIC
    -29.2%
    ROE
    -30.2%
    FCF margin
    -24.1%
    FCF yield
    -7.2%

    PRCT Competitors

    CompanyTicker
    Nektar TherapeuticsNKTR
    Tourmaline Bio Inc.TRML
    Omeros CorporationOMER
    Silence Therapeutics PLCSLN
    InnovAge Holding CorpINNV
    Compass Pathways PlcCMPS
    Tandem Diabetes Care IncTNDM
    MannKind CorpMNKD

    Sector: Healthcare

    PRCT Analyst Ratings

    Consensus
    Hold
    Analysts
    14
    Strong Buy
    1
    Buy
    3
    Hold
    9
    Sell
    0
    Strong Sell
    1

    PRCT Bull Case vs Bear Case

    Bull case

    • PRCT grew quarterly revenue 19.3% year over year.

    Bear case

    • PRCT has a -32.5% net profit margin.
    • PRCT beat EPS estimates in 37.5% of its last 8 reported quarters.

    PRCT Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -6.8%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.27

    PRCT Earnings Date

    PRCT reports Feb 23, 2027, after the close. The date is estimated.

    PRCT Earnings Call

    The latest PRCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    PRCT ETF Holders

    GNG tracks 11 ETFs that hold PRCT. The largest weights:

    1. State Street SPDR S&P Health Care Equipment ETF (XHE), 1.50% of the fund
    2. iShares U.S. Medical Devices ETF (IHI), 0.15% of the fund
    3. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.13% of the fund
    4. iShares Russell 2000 ETF (IWM), 0.07% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.06% of the fund
    Open the ETF Stock Exposure tool for PRCT

    See insider activity

    Frequently Asked Questions About PRCT

    When does PRCT report earnings?

    Procept Biorobotics Corp (PRCT) is expected to report earnings on Feb 23, 2027.

    Does PRCT pay dividends?

    Procept Biorobotics Corp (PRCT) does not currently pay a regular dividend.

    What is PRCT's market cap?

    Procept Biorobotics Corp (PRCT) has a market capitalization of $1.23B with a current stock price of $20.62.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In